Press Release
<< Back
Timothy J. Barberich Joins Verastem Board of Directors
“Tim is an entrepreneur at heart who has become a very successful
biopharmaceutical business leader,” said
Mr. Barberich founded
"Tim's extensive experience in guiding successful biopharmaceutical
companies will be invaluable to
About Verastem, Inc.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, the timeline for
clinical development and regulatory approval of the Company’s compounds,
the expected timing for the reporting of data from ongoing trials, and
the structure of the Company’s planned or pending clinical trials, and
potential indications for clinical development. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s compounds and preliminary data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that the Company will be unable to successfully
complete the clinical development of its compounds, that the development
of the Company’s compounds will take longer or cost more than planned,
and that the Company’s compounds will not receive regulatory approval or
become commercially successful products. Other risks and uncertainties
include those identified under the heading “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com